Message sent on behalf of Howard Stokoe, Commercial Medicines Unit, and Dr Keith Ridge, Chief Pharmaceutical Officer
Interruption to supply: Tinzaparin sodium (Innohep ® LEO Laboratories Ltd ) 10,000 IU/ml Syringe presentations:
- 2,500IU anti-Factor Xa IU in 0.25ml
- 3,500IU anti-Factor Xa IU in 0.35ml
- 4,500IU anti-Factor Xa IU in 0.45ml
LEO has written to Healthcare Professionals explaining that there will be interruptions to the supply of its three syringe presentations of tinzaparin sodium 10,000 IU/ml. A copy of this letter is attached.
The quantities of tinzaparin 10,000 IU/ml syringes available within the UK supply chain are extremely limited and the problem is expected to last until January 2012.
This means that NHS trusts and clinicians will have no choice but to manage existing stocks, review local protocols and transfer patients to the use of alternative products.
I have attached copies of the communication from Howard Stokoe, the letter from LEO, and guidance on switching to alternative products.
Patients should be advised to return to their prescriber for advice/switching to an alternative product.
I would be grateful if you would circulate this information through your networks so that primary care pharmacists are aware of the issue and can provide support to patients, prescribers and community pharmacists.
It would also be very useful if you could let me know how great an impact this issue may present in primary care. In East London and the City, we have a number of patients prescribed tinzaparin in the community under a shared-care protocol, so I assume that similar arrangements will be in place elsewhere.
National Clinical Director for Primary Care and Community Pharmacy
Department of Health
CMU re tinzaparin